FDA Approves Merck's Winrevair For Treatment Of Pulmonary Arterial Hypertension In Adults
27/3 04:41
(RTTNews) - Merck & Co., Inc. (MRK) said that the U.S. Food and Drug Administration has approved sotatercept-csrk (U.S. Brand Name: Winrevair, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO fu...